The Diabetes Prevention Program

Design and methods for a clinical trial in the prevention of type 2 diabetes

G. A. Bray, K. S. Polonsky, P. G. Watson, R. B. Goldberg, S. M. Haffner, R. F. Hamman, E. S. Horton, S. F. Kahn, A. E. Kitabchi, B. E. Metzger, D. M. Nathan, J. M. Olefsky, F. X. Pi-Sunyer, M. J. Prince, R. E. Ratner, M. F. Saad, Samuel Dagogo-Jack, C. D. Saudek, D. S. Schade, H. Shamoon & 9 others R. R. Wing, R. F. Arakaki, W. C. Krowler, R. Bain, S. M. Marcovina, P. M. Rautaharju, E. J. Mayer-Davis, D. H. O'Leary, E. R. Stamm

Research output: Contribution to journalReview article

471 Citations (Scopus)

Abstract

The Diabetes Prevention Program is a randomized clinical trial testing strategies to prevent or delay the development of type 2 diabetes in high- risk individuals with elevated fasting plasma glucose concentrations and impaired glucose tolerance. The 27 clinical centers in the U.S. are recruiting at least 3,000 participants of both sexes, ~50% of whom are minority patients and 20% of whom are ≥65 years old, to be assigned at random to one of three intervention groups: an intensive lifestyle intervention focusing on a healthy diet and exercise and two masked medication treatment groups - metformin or placebo - combined with standard diet and exercise recommendations. Participants are being recruited during a 2 2/3-year period, and all will be followed for an additional 3 1/3 to 5 years after the close of recruitment to a common closing date in 2002. The primary outcome is the development of diabetes, diagnosed by fasting or post- challenge plasma glucose concentrations meeting the 1997 American Diabetes Association criteria. The 3,000 participants will provide 90% power to detect a 33% reduction in an expected diabetes incidence rate of at least 6.5% per year in the placebo group. Secondary outcomes include cardiovascular disease and its risk factors; changes in glycemia, β-cell function, insulin sensitivity, obesity, diet, physical activity, and health-related quality of life; and occurrence of adverse events. A fourth treatment group - troglitazone combined with standard diet and exercise recommendations - was included initially but discontinued because of the liver toxicity of the drug. This randomized clinical trial will test the possibility of preventing or delaying the onset of type 2 diabetes in individuals at high risk.

Original languageEnglish (US)
Pages (from-to)623-634
Number of pages12
JournalDiabetes care
Volume22
Issue number4
DOIs
StatePublished - Jan 1 1999
Externally publishedYes

Fingerprint

Type 2 Diabetes Mellitus
Clinical Trials
Exercise
troglitazone
Diet
Fasting
Randomized Controlled Trials
Placebos
Glucose
Glucose Intolerance
Metformin
Drug-Related Side Effects and Adverse Reactions
Insulin Resistance
Life Style
Cardiovascular Diseases
Obesity
Quality of Life
Liver
Incidence
Therapeutics

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Cite this

Bray, G. A., Polonsky, K. S., Watson, P. G., Goldberg, R. B., Haffner, S. M., Hamman, R. F., ... Stamm, E. R. (1999). The Diabetes Prevention Program: Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes care, 22(4), 623-634. https://doi.org/10.2337/diacare.22.4.623

The Diabetes Prevention Program : Design and methods for a clinical trial in the prevention of type 2 diabetes. / Bray, G. A.; Polonsky, K. S.; Watson, P. G.; Goldberg, R. B.; Haffner, S. M.; Hamman, R. F.; Horton, E. S.; Kahn, S. F.; Kitabchi, A. E.; Metzger, B. E.; Nathan, D. M.; Olefsky, J. M.; Pi-Sunyer, F. X.; Prince, M. J.; Ratner, R. E.; Saad, M. F.; Dagogo-Jack, Samuel; Saudek, C. D.; Schade, D. S.; Shamoon, H.; Wing, R. R.; Arakaki, R. F.; Krowler, W. C.; Bain, R.; Marcovina, S. M.; Rautaharju, P. M.; Mayer-Davis, E. J.; O'Leary, D. H.; Stamm, E. R.

In: Diabetes care, Vol. 22, No. 4, 01.01.1999, p. 623-634.

Research output: Contribution to journalReview article

Bray, GA, Polonsky, KS, Watson, PG, Goldberg, RB, Haffner, SM, Hamman, RF, Horton, ES, Kahn, SF, Kitabchi, AE, Metzger, BE, Nathan, DM, Olefsky, JM, Pi-Sunyer, FX, Prince, MJ, Ratner, RE, Saad, MF, Dagogo-Jack, S, Saudek, CD, Schade, DS, Shamoon, H, Wing, RR, Arakaki, RF, Krowler, WC, Bain, R, Marcovina, SM, Rautaharju, PM, Mayer-Davis, EJ, O'Leary, DH & Stamm, ER 1999, 'The Diabetes Prevention Program: Design and methods for a clinical trial in the prevention of type 2 diabetes', Diabetes care, vol. 22, no. 4, pp. 623-634. https://doi.org/10.2337/diacare.22.4.623
Bray, G. A. ; Polonsky, K. S. ; Watson, P. G. ; Goldberg, R. B. ; Haffner, S. M. ; Hamman, R. F. ; Horton, E. S. ; Kahn, S. F. ; Kitabchi, A. E. ; Metzger, B. E. ; Nathan, D. M. ; Olefsky, J. M. ; Pi-Sunyer, F. X. ; Prince, M. J. ; Ratner, R. E. ; Saad, M. F. ; Dagogo-Jack, Samuel ; Saudek, C. D. ; Schade, D. S. ; Shamoon, H. ; Wing, R. R. ; Arakaki, R. F. ; Krowler, W. C. ; Bain, R. ; Marcovina, S. M. ; Rautaharju, P. M. ; Mayer-Davis, E. J. ; O'Leary, D. H. ; Stamm, E. R. / The Diabetes Prevention Program : Design and methods for a clinical trial in the prevention of type 2 diabetes. In: Diabetes care. 1999 ; Vol. 22, No. 4. pp. 623-634.
@article{e88653fc681c42e599662751e01a77bd,
title = "The Diabetes Prevention Program: Design and methods for a clinical trial in the prevention of type 2 diabetes",
abstract = "The Diabetes Prevention Program is a randomized clinical trial testing strategies to prevent or delay the development of type 2 diabetes in high- risk individuals with elevated fasting plasma glucose concentrations and impaired glucose tolerance. The 27 clinical centers in the U.S. are recruiting at least 3,000 participants of both sexes, ~50{\%} of whom are minority patients and 20{\%} of whom are ≥65 years old, to be assigned at random to one of three intervention groups: an intensive lifestyle intervention focusing on a healthy diet and exercise and two masked medication treatment groups - metformin or placebo - combined with standard diet and exercise recommendations. Participants are being recruited during a 2 2/3-year period, and all will be followed for an additional 3 1/3 to 5 years after the close of recruitment to a common closing date in 2002. The primary outcome is the development of diabetes, diagnosed by fasting or post- challenge plasma glucose concentrations meeting the 1997 American Diabetes Association criteria. The 3,000 participants will provide 90{\%} power to detect a 33{\%} reduction in an expected diabetes incidence rate of at least 6.5{\%} per year in the placebo group. Secondary outcomes include cardiovascular disease and its risk factors; changes in glycemia, β-cell function, insulin sensitivity, obesity, diet, physical activity, and health-related quality of life; and occurrence of adverse events. A fourth treatment group - troglitazone combined with standard diet and exercise recommendations - was included initially but discontinued because of the liver toxicity of the drug. This randomized clinical trial will test the possibility of preventing or delaying the onset of type 2 diabetes in individuals at high risk.",
author = "Bray, {G. A.} and Polonsky, {K. S.} and Watson, {P. G.} and Goldberg, {R. B.} and Haffner, {S. M.} and Hamman, {R. F.} and Horton, {E. S.} and Kahn, {S. F.} and Kitabchi, {A. E.} and Metzger, {B. E.} and Nathan, {D. M.} and Olefsky, {J. M.} and Pi-Sunyer, {F. X.} and Prince, {M. J.} and Ratner, {R. E.} and Saad, {M. F.} and Samuel Dagogo-Jack and Saudek, {C. D.} and Schade, {D. S.} and H. Shamoon and Wing, {R. R.} and Arakaki, {R. F.} and Krowler, {W. C.} and R. Bain and Marcovina, {S. M.} and Rautaharju, {P. M.} and Mayer-Davis, {E. J.} and O'Leary, {D. H.} and Stamm, {E. R.}",
year = "1999",
month = "1",
day = "1",
doi = "10.2337/diacare.22.4.623",
language = "English (US)",
volume = "22",
pages = "623--634",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "4",

}

TY - JOUR

T1 - The Diabetes Prevention Program

T2 - Design and methods for a clinical trial in the prevention of type 2 diabetes

AU - Bray, G. A.

AU - Polonsky, K. S.

AU - Watson, P. G.

AU - Goldberg, R. B.

AU - Haffner, S. M.

AU - Hamman, R. F.

AU - Horton, E. S.

AU - Kahn, S. F.

AU - Kitabchi, A. E.

AU - Metzger, B. E.

AU - Nathan, D. M.

AU - Olefsky, J. M.

AU - Pi-Sunyer, F. X.

AU - Prince, M. J.

AU - Ratner, R. E.

AU - Saad, M. F.

AU - Dagogo-Jack, Samuel

AU - Saudek, C. D.

AU - Schade, D. S.

AU - Shamoon, H.

AU - Wing, R. R.

AU - Arakaki, R. F.

AU - Krowler, W. C.

AU - Bain, R.

AU - Marcovina, S. M.

AU - Rautaharju, P. M.

AU - Mayer-Davis, E. J.

AU - O'Leary, D. H.

AU - Stamm, E. R.

PY - 1999/1/1

Y1 - 1999/1/1

N2 - The Diabetes Prevention Program is a randomized clinical trial testing strategies to prevent or delay the development of type 2 diabetes in high- risk individuals with elevated fasting plasma glucose concentrations and impaired glucose tolerance. The 27 clinical centers in the U.S. are recruiting at least 3,000 participants of both sexes, ~50% of whom are minority patients and 20% of whom are ≥65 years old, to be assigned at random to one of three intervention groups: an intensive lifestyle intervention focusing on a healthy diet and exercise and two masked medication treatment groups - metformin or placebo - combined with standard diet and exercise recommendations. Participants are being recruited during a 2 2/3-year period, and all will be followed for an additional 3 1/3 to 5 years after the close of recruitment to a common closing date in 2002. The primary outcome is the development of diabetes, diagnosed by fasting or post- challenge plasma glucose concentrations meeting the 1997 American Diabetes Association criteria. The 3,000 participants will provide 90% power to detect a 33% reduction in an expected diabetes incidence rate of at least 6.5% per year in the placebo group. Secondary outcomes include cardiovascular disease and its risk factors; changes in glycemia, β-cell function, insulin sensitivity, obesity, diet, physical activity, and health-related quality of life; and occurrence of adverse events. A fourth treatment group - troglitazone combined with standard diet and exercise recommendations - was included initially but discontinued because of the liver toxicity of the drug. This randomized clinical trial will test the possibility of preventing or delaying the onset of type 2 diabetes in individuals at high risk.

AB - The Diabetes Prevention Program is a randomized clinical trial testing strategies to prevent or delay the development of type 2 diabetes in high- risk individuals with elevated fasting plasma glucose concentrations and impaired glucose tolerance. The 27 clinical centers in the U.S. are recruiting at least 3,000 participants of both sexes, ~50% of whom are minority patients and 20% of whom are ≥65 years old, to be assigned at random to one of three intervention groups: an intensive lifestyle intervention focusing on a healthy diet and exercise and two masked medication treatment groups - metformin or placebo - combined with standard diet and exercise recommendations. Participants are being recruited during a 2 2/3-year period, and all will be followed for an additional 3 1/3 to 5 years after the close of recruitment to a common closing date in 2002. The primary outcome is the development of diabetes, diagnosed by fasting or post- challenge plasma glucose concentrations meeting the 1997 American Diabetes Association criteria. The 3,000 participants will provide 90% power to detect a 33% reduction in an expected diabetes incidence rate of at least 6.5% per year in the placebo group. Secondary outcomes include cardiovascular disease and its risk factors; changes in glycemia, β-cell function, insulin sensitivity, obesity, diet, physical activity, and health-related quality of life; and occurrence of adverse events. A fourth treatment group - troglitazone combined with standard diet and exercise recommendations - was included initially but discontinued because of the liver toxicity of the drug. This randomized clinical trial will test the possibility of preventing or delaying the onset of type 2 diabetes in individuals at high risk.

UR - http://www.scopus.com/inward/record.url?scp=0033030445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033030445&partnerID=8YFLogxK

U2 - 10.2337/diacare.22.4.623

DO - 10.2337/diacare.22.4.623

M3 - Review article

VL - 22

SP - 623

EP - 634

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 4

ER -